Discover an informative webinar that delves into the successes and failures of using real-world data and evidence in regulatory approvals.
The business of drug development and commercialization is undergoing a transformative shift, driven by the growing acceptance of real-world data/evidence in regulatory and reimbursement decision-making, coupled with unprecedented advancements in data analytics technologies.
In this webinar, the speakers will explore the profound implications of this convergence for pharmaceutical manufacturers and offer actionable insights into how to leverage these trends to optimize product development, reduce costs and maximize market access. The attendees will also get to discover how organizations can harness these powerful tools to drive innovation and improve clinical care.
Read more...
The attendees will also learn how to leverage real-world data and evidence to optimize patient recruitment, refine study designs and validate clinical hypotheses. The speakers will also demonstrate how real-world data and evidence can support negotiations by showcasing real-world effectiveness and value and help develop compelling value propositions for payers and health technology assessment (HTA) bodies.
They will also address challenges associated with real-world data and evidence such as data privacy concerns, methodological limitations and integration issues, as well as share best practices for data collection, analysis and interpretation. Finally, they will explore how advanced analytics, including machine learning and artificial intelligence, are enhancing real-world data and evidence analysis to drive product development decisions.
Read Less...
Register for this webinar to gain invaluable insights into how real-world data and advanced analytics are reshaping the future of drug development and commercialization.
Speakers
Stephanie Butler, PharmD, Principle Practice Lead, Anlitiks
Stephanie Butler, PharmD, is a seasoned healthcare consultant specializing in data-driven market access solutions. Based in Austin, Texas, Stephanie brings over 20 years of experience in devising strategic solutions that bridge the gap between life-changing therapies and patient access and affordability.
As the Principal Practice Lead at Anlitiks Inc., a consultancy revolutionizing the way real-world data is transformed into actionable insights, Stephanie helps life-science companies address critical challenges in product development and market access through data-driven solutions, such as treatment/competitive landscape assessments, target population optimization, product value propositions and robust reimbursement and pricing strategies.
Read more...
Read Less...
Kitty Rajagopalan, PhD, President & Chief Scientific Officer, Anlitiks
Krithika “Kitty” Rajagopalan, PhD, MPH, is the President & Chief Scientific Officer of Anlitiks Inc., an emerging, disruptive, tech-services consultancy in HEOR, RWE and market access. She is a life sciences industry veteran and well-published executive with nearly 30 years’ experience in the field of HEOR, RWE, Pricing and Market Access.
Her multi-therapeutic area experience includes oncology, neurosciences, cardiovascular, immunology and rare disease therapy areas. Her notable experience includes first-in-class PRO label claims across multiple therapeutic areas and successful track record of successful HTA assessments (NICE, PBAC, SMC, CDR and other HTA bodies and US Public/Private payors). She is also the owner of copyrights of PRO instruments and has authored over 125+ manuscripts in peer-reviewed journals and presented over 650+ scientific papers.
Read more...
Read Less...
Who Should Attend?
This webinar will appeal to:
- Pharmaceutical executives and decision-makers
- R&D professionals
- Medical affairs and market access teams
- Health economists and outcomes researchers
- Data scientists and technology specialists
What You Will Learn
Attendees will learn about:
- Case studies highlighting both the successes and challenges of using real-world data and evidence for regulatory submissions
- How real-world data and evidence can revolutionize the drug development process
- Real-world data and evidence’s impact on pricing, reimbursement and market access
- Challenges associated with real-world data and evidence, including data privacy concerns, methodological limitations and integration with existing systems
- Harnessing advanced analytics to maximize real-world data and evidence potential
Xtalks Partner
Anlitiks
Anlitiks, a pioneering force at the intersection of technology and science, revolutionizing the way real-world data is transformed into actionable insights. At Anlitiks, our core mission is to empower the life sciences sector by providing swift and efficient analysis of real-world data, turning it into evidence that fosters the development of superior therapeutic solutions and enhances patient health outcomes.
Our unique data-agnostic analytic platform-service model, RapidAnalyzer™, is designed to lead the industry in translating complex data into valuable evidence in real-time. We are committed to improving healthcare outcomes through our expertise in real-world evidence generation, market access, and HEOR-related activities. Our consultative approach and dedication to data-driven decision-making enable us to address critical challenges in product development and payment innovation, impacting healthcare globally.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account